IQVIA (IQV) Stock Forecast & Price Target

IQVIA logo
$258.19 -6.54 (-2.47%)
As of 03:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

IQVIA - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
2
Buy
18

Based on 21 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 1 has given a sell rating, 2 have given a hold rating, 16 have given a buy rating, and 2 have given a strong buy rating for IQV.

Consensus Price Target

$294.21
13.95% Upside
According to the 21 analysts' twelve-month price targets for IQVIA, the average price target is $294.21. The highest price target for IQV is $346.00, while the lowest price target for IQV is $200.00. The average price target represents a forecasted upside of 13.95% from the current price of $258.19.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for IQV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IQV Analyst Ratings Over Time

TypeCurrent Forecast
11/17/25 to 11/17/26
1 Month Ago
10/18/25 to 10/18/26
3 Months Ago
8/19/25 to 8/19/26
1 Year Ago
11/17/24 to 11/17/25
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
2 Strong Buy rating(s)
Buy
16 Buy rating(s)
16 Buy rating(s)
16 Buy rating(s)
14 Buy rating(s)
Hold
2 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$294.21$274.76$241.60$240.74
Forecasted Upside13.95% Upside2.91% Upside-3.21% Downside11.33% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

IQVIA Stock vs. The Competition

TypeIQVIAHealthcare CompaniesBroader Market
Consensus Rating Score
2.90
2.32
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside10.96% Upside115.64% Upside16.13% Upside
News Sentiment Rating
Positive News

See Recent IQV News
Positive News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/29/2026
TD Cowen logo
TD Cowen
3 of 5 stars
Charles Rhyee
Charles Rhyee
4 of 5 stars
Boost TargetBuy$288.00 ➝ $307.00+11.07%
10/28/2026
Weiss Ratings logo
Weiss Ratings
2 of 5 stars
 DowngradeHold (C+) ➝ Sell (D+)
10/28/2026
Truist Financial Corporation logo
Truist Financial
2 of 5 stars
Jailendra Singh
Jailendra Singh
1 of 5 stars
Boost TargetBuy$329.00 ➝ $346.00+24.14%
10/28/2026Boost TargetOverweight$295.00 ➝ $325.00+17.55%
10/27/2026Boost TargetOutperform$324.00 ➝ $328.00+20.36%
10/19/2026Boost Target$270.00 ➝ $305.00+9.53%
10/15/2026 Lower Target$191.00 ➝ $179.00-35.72%
10/14/2026Boost TargetBuy$276.00 ➝ $303.00+16.21%
10/8/2026 Boost TargetOutperform$280.00 ➝ $310.00+11.25%
10/7/2026Boost TargetOutperform$275.00 ➝ $300.00+16.55%
10/7/2026Boost TargetOverweight$275.00 ➝ $300.00+15.30%
10/6/2026 Boost TargetOutperform$275.00 ➝ $290.00+4.07%
9/30/2026Initiated CoverageBuy$345.00+28.31%
9/29/2026Boost TargetOutperform$247.00 ➝ $319.00+17.71%
9/17/2026Boost TargetEqual Weight$240.00 ➝ $270.00-0.92%
9/1/2026Boost TargetBuy$280.00 ➝ $300.00+7.66%
7/29/2026 Boost TargetBuy$220.00 ➝ $290.00+4.07%
7/29/2026 Boost TargetBuy$284.00 ➝ $287.00+2.99%
7/28/2026 UpgradeStrong-Buy
7/7/2026 Boost Target$215.00 ➝ $235.00-15.67%
2/6/2026Lower TargetNeutral$230.00 ➝ $200.00+6.68%
10/29/2025 Boost TargetOverweight$220.00 ➝ $250.00-10.34%
10/20/2025 Boost Target$215.00 ➝ $230.00-17.51%
2/3/2025DowngradeBuy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:14 PM ET.


Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, November 17, 2026. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com.

IQVIA
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

  • IQVIA Holdings Inc. recently reported third-quarter earnings that exceeded analyst expectations, with earnings per share of $3.34 beating the consensus estimate of $3.26, while revenue of $4.43 billion also surpassed the projected $4.37 billion, demonstrating strong operational performance and demand for its clinical research services.
  • The company has shown consistent year-over-year revenue growth, with the most recent quarter seeing an 8.0% increase, and the prior quarter in July 2026 showing an 8.7% increase, indicating a stable and expanding business model driven by rising clinical research demand and commercial services momentum.
  • Wall Street analysts maintain a positive outlook on the stock, with a consensus rating of "Moderate Buy" and a consensus price target of $294.21, which is significantly higher than the current stock price of $258.99, suggesting potential for further upside as firms like JPMorgan Chase and HSBC recently raised their price targets.
  • IQVIA Holdings Inc. is benefiting from the integration of artificial intelligence into its operations, as highlighted by recent market reports on AI clinical trial optimization, which is expected to boost profitability and operational efficiencies for the company and its clients in the life sciences industry.
  • Institutional investors are increasing their exposure to the company, with several firms such as Pictet Asset Management and Mirae Asset Global Investments adding to their positions or initiating new stakes in the third quarter, reflecting growing confidence in the company's long-term value proposition.

IQVIA
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

  • Insider selling activity has been notable recently, with insider Eric Sherbet selling 4,446 shares on November 9, 2026, and other insiders such as James G. Berkshire and Bhavik Patel also selling shares in the past few months, which may signal a lack of confidence from those with the most knowledge of the company's internal operations.
  • The company carries a high debt-to-equity ratio of 2.18, which indicates a significant level of leverage relative to its equity, potentially increasing financial risk and interest expenses that could impact future earnings if interest rates remain elevated or if revenue growth slows.
  • Short interest in the stock has been relatively high, with approximately 3.04 million shares shorted as of the most recent record date, representing about 1.88% of the float, which suggests that a portion of the market is betting against the stock's performance and could lead to volatility if short sellers continue to add to their positions.
  • The current stock price of $258.99 is below the 52-week high of $284.50, and the stock has experienced recent declines, such as the drop to $271.11 on Thursday, indicating that the stock may be facing headwinds or that investors are taking profits after a period of significant gains.
  • Some analysts have expressed caution, with Deutsche Bank reducing its price target on IQVIA Holdings Inc. from $191.00 to $179.00 in October 2026, and one analyst maintaining a "Sell" rating, suggesting that there are concerns about the company's valuation or future growth prospects that not all market participants share.

IQV Forecast - Frequently Asked Questions

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $294.21, with a high forecast of $346.00 and a low forecast of $200.00.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last year. There is currently 1 sell rating, 2 hold ratings, 16 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IQV shares.

According to analysts, IQVIA's stock has a predicted upside of 13.95% based on their 12-month stock forecasts.

Over the previous 90 days, IQVIA's stock had 2 upgrades and 1 downgrade by analysts.

Analysts like IQVIA more than other "healthcare" companies. The consensus rating for IQVIA is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how IQV compares to other companies.


MarketBeat monitors more than a dozen sources for IQVIA analyst ratings, with the most recent rating issued on 10/29/2026.
From Our Partners